Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Bimekizumab in Chronic Plaque Psoriasis
NCT03598790Phase 3Completed
- Sponsor
- UCB
- Start
- Sep 2018
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of bimekizumab in psoriasis, sponsored by UCB. Started Sep 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03598790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598790.